PREVNAR + C295 ISS VACCINE FORMULATION IN INFANT BABOONS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to test for the first time in infant baboons the immunogenicity of a commercial pneumococcal 7-valent vaccine formulation (PREVNAR¿) alone, or in combination immunostimulatory DNA sequences (C295 ISS and C295-PMXB). PREVNAR¿ vaccine in combination with C295 ISS or C295-PMXB was tested in adult baboons (952-PC-0) and was shown to be safe. This study will help decide if PREVNAR¿ combined with C295 ISS or C295-PMXB vaccine formulation can elicit improved antibody responses in infant baboons to pneumococcal polysaccharide antigens, which will assist in the development of a new pneumococcal vaccine for human infants.